Onconetix receives additional notice from Nasdaq

Onconetix (ONCO) announced that it received a Staff delisting letter from The Nasdaq Capital Market on April 24, 2025 indicating that the company’s failure to file its Annual Report on Form 10-K for the fiscal year ended December 30, 2024 is in violation of Nasdaq’s continued listing requirements under Nasdaq Listing Rule 5250(c)(1). This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.